We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study.
- Authors
van Oers, Marinus H J; Tönnissen, Evelyn; Van Glabbeke, Martine; Giurgea, Livia; Jansen, Joop H; Klasa, Richard; Marcus, Robert E; Wolf, Max; Kimby, Eva; Vranovsky, Andrej; Holte, Harald; Hagenbeek, Anton; van der Reijden, Bert A
- Abstract
The prognostic value of residual BCL2/immunoglobulin heavy chain (BCL2/IgH) -positive cells in peripheral blood (PB) or bone marrow (BM) after induction treatment in follicular lymphoma (FL) is still controversial. In a prospective randomized phase III intergroup trial of 465 patients with relapsed/resistant follicular lymphoma (FL), we showed that addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone induction results in increased overall and complete response rates, and that rituximab maintenance strongly improves median progression-free survival (PFS) as well as overall survival. Here, we studied whether BCL2/IgH major break point levels in PB/BM correlated with response rates/quality for the induction phase and PFS for the maintenance phase.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Vol 28, Issue 13, p2246
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2009.25.0852